stringtranslate.com

List of infectious diseases

This is a list of infectious diseases arranged by name, along with the infectious agents that cause them, the vaccines that can prevent or cure them when they exist and their current status. Some on the list are vaccine-preventable diseases.

List

See also

References

  1. ^ Kuschner, R. A.; Russell, K. L.; Abuja, M.; Bauer, K. M.; Faix, D. J.; Hait, H.; Henrick, J.; Jacobs, M.; Liss, A.; Lynch, J. A.; Liu, Q.; Lyons, A. G.; Malik, M.; Moon, J. E.; Stubbs, J.; Sun, W.; Tang, D.; Towle, A. C.; Walsh, D. S.; Wilkerson, D.; Adenovirus Vaccine Efficacy Trial Consortium (2013). "A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. Military recruits". Vaccine. 31 (28): 2963–2971. doi:10.1016/j.vaccine.2013.04.035. PMID 23623865.
  2. ^ "Trypanosomiasis, human African (sleeping sickness)". World Health Organization. 2 May 2023. Retrieved 2023-06-16.
  3. ^ La Greca, F.; Magez, S. (2011). "Vaccination against trypanosomiasis: Can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?". Human Vaccines. 7 (11): 1225–1233. doi:10.4161/hv.7.11.18203. PMC 3323498. PMID 22205439.
  4. ^ "Researchers a step closer to making HIV vaccine". Medical News Today. April 5, 2013. Retrieved April 24, 2013.
  5. ^ Enria, Delia A.; Ambrosio, Ana M.; Briggiler, Ana M.; Feuillade, María R.; Crivelli, Eleonora; Grupo de Estudio de la Vacuna contra la Fiebre Hemorrágica Argentina (2010). "Vacuna contra la Fiebre Hemorragica Argentina Candid#1 producida en la Argentina. Inmunogenicidad y seguridad" [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety] (PDF). Medicina (in Spanish). 70 (3): 215–22. PMID 20529769.
  6. ^ Negrón, María E.; Kharod, Grishma A.; Bower, William A.; Walke, Henry (22 February 2019). "Notes from the Field: Human Brucella abortus RB51 Infections Caused by Consumption of Unpasteurized Domestic Dairy Products — United States, 2017–2019". Morbidity and Mortality Weekly Report. 68 (7): 185. doi:10.15585/mmwr.mm6807a6. PMC 6385706. PMID 30789879.
  7. ^ a b Titball, R. W.; Williamson, E. D. (2004). "Yersinia pestis (plague) vaccines". Expert Opinion on Biological Therapy. 4 (6): 965–973. doi:10.1517/14712598.4.6.965. PMID 15174978. S2CID 43565534.
  8. ^ Shivakumar, K. M.; Vidya, S. K.; Chandu, G. N. (2009). "Dental caries vaccine". Indian Journal of Dental Research. 20 (1): 99–106. doi:10.4103/0970-9290.49066. PMID 19336869.
  9. ^ "Chagas disease (also known as American trypanosomiasis)". World Health Organization. 4 April 2024. Archived from the original on Jun 25, 2024.
  10. ^ "Potential Chagas Vaccine Candidate Shows Unprecedented Efficacy". Science Daily. 26 March 2013. Retrieved 14 September 2013.
  11. ^ Docksai, Rick (31 May 2017). "DoD Vaccine Research Saves Military, Civilian Lives". US Department of Defense. Retrieved 7 July 2018.
  12. ^ Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines". Expert Opinion on Biological Therapy. 10 (2): 179–190. doi:10.1517/14712590903379502. PMID 20088713. S2CID 2700243.
  13. ^ Schleiss, M. R. (2008). "Cytomegalovirus vaccine development". Human Cytomegalovirus. Current Topics in Microbiology and Immunology. Vol. 325. pp. 361–382. doi:10.1007/978-3-540-77349-8_20. ISBN 978-3-540-77348-1. PMC 2831992. PMID 18637516.
  14. ^ Pandya, J.; Gorchakov, R.; Wang, E.; Leal, G.; Weaver, S. C. (2012). "A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation". Vaccine. 30 (7): 1276–1282. doi:10.1016/j.vaccine.2011.12.121. PMC 3283035. PMID 22222869.
  15. ^ Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012). "Evaluation of an attenuated strain of Ehrlichia canis as a vaccine for canine monocytic ehrlichiosis". Vaccine. 31 (1): 226–233. doi:10.1016/j.vaccine.2012.10.003. PMID 23072894.
  16. ^ "Collaboration to develop the world's first prophylactic gonorrhoea vaccine". Archived from the original on 2020-09-02.
  17. ^ Zhu, F. C.; Liang, Z. L.; Li, X. L.; Ge, H. M.; Meng, F. Y.; Mao, Q. Y.; Zhang, Y. T.; Hu, Y. M.; Zhang, Z. Y.; Li, J. X.; Gao, F.; Chen, Q. H.; Zhu, Q. Y.; Chu, K.; Wu, X.; Yao, X.; Guo, H. J.; Chen, X. Q.; Liu, P.; Dong, Y. Y.; Li, F. X.; Shen, X. L.; Wang, J. Z. (2013). "Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial". The Lancet. 381 (9871): 1037–45. doi:10.1016/S0140-6736(12)61764-4. PMID 23352749. S2CID 27961719.
  18. ^ Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines". Expert Opinion on Biological Therapy. 10 (2): 179–190. doi:10.1517/14712590903379502. PMID 20088713. S2CID 2700243.
  19. ^ "Hepatitis C vaccine by Inovio could be tested in humans by end of year". Philadelphia Business Journal. January 9, 2013. Retrieved April 24, 2013.
  20. ^ "Human hookworm vaccine trial". Medical News Today. January 20, 2012. Retrieved April 24, 2013.
  21. ^ Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. (5 December 2001). "Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity". Journal of the National Cancer Institute. 93 (23): 1775–1783. doi:10.1093/jnci/93.23.1775. PMID 11734593.
  22. ^ De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (2007). "Human T Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine". Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers. Novartis Foundation Symposia. Vol. 187. pp. 47–60. doi:10.1002/9780470514672.ch4. ISBN 978-0-470-51467-2. PMID 7796676.
  23. ^ Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. (2001). "Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity". Journal of the National Cancer Institute. 93 (23): 1775–1783. doi:10.1093/jnci/93.23.1775. PMID 11734593.
  24. ^ De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (1994). "Human T Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine". Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers. Novartis Foundation Symposia. Vol. 187. pp. 47–55, discussion 55–60. doi:10.1002/9780470514672.ch4. ISBN 9780470514672. PMID 7796676. {{cite book}}: |journal= ignored (help)
  25. ^ Pullen, L.C. (November 7, 2011). "Epstein-Barr Virus Vaccine May Soon Enter Phase 3 Trial". Medscape Today. Retrieved April 24, 2013.
  26. ^ "H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, Inc. Questions and Answers". FDA. 12 April 2019.
  27. ^ Nakkazi, E. (March 12, 2012). "New vaccine trials to prevent visceral leishmaniasis". New Science Journalism. Retrieved June 16, 2013.
  28. ^ "Leprosy". World Health Organization. 27 January 2023. Retrieved 2023-06-16.
  29. ^ McGuinness, R. (November 20, 2012). "Search for leprosy vaccine continues as disease still affects thousands". Metro News. Retrieved May 29, 2013.
  30. ^ "Lyme Disease Vaccine". Lyme Info. Retrieved April 24, 2013.
  31. ^ "Lymphatic filariasis". World Health Organization. 1 June 2023. Retrieved 2023-06-16.
  32. ^ Hampton, T. (2006). "Marburg Vaccine Shows Promise: Offers Postexposure Protection in Monkeys". JAMA. 295 (20): 2346. doi:10.1001/jama.295.20.2346. PMID 16720816.
  33. ^ "Measles". World Health Organization. Retrieved 2023-06-16.
  34. ^ "MERS vaccine shows promise in clinical trial, say researchers". Archived from the original on 2020-05-03.
  35. ^ "Developing a vaccine against Nipah virus".
  36. ^ Sifferlin, A. (March 22, 2013). "Norovirus leading cause of intestinal disorders in kids". CNN. Retrieved April 24, 2013.
  37. ^ "Onchocerciasis". World Health Organization. 11 January 2022. Retrieved 2023-06-16.
  38. ^ Sanjit Bagchi (April 26, 2006). "Study raises hopes of vaccine for river blindness". SciDev Net. Retrieved April 24, 2013.
  39. ^ "Rabies". World Health Organization. Retrieved 2023-06-16.
  40. ^ Lindell, D. M.; Morris, S. B.; White, M. P.; Kallal, L. E.; Lundy, P. K.; Hamouda, T.; Baker, J. R.; Lukacs, N. W. (2011). Semple, Malcolm Gracie (ed.). "A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease". PLOS ONE. 6 (7): e21823. Bibcode:2011PLoSO...621823L. doi:10.1371/journal.pone.0021823. PMC 3137595. PMID 21789184.
  41. ^ "Rubella". World Health Organization. Retrieved 2023-06-16.
  42. ^ Jiang, S.; Lu, L.; Du, L. (2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
  43. ^ "Schistosomiasis". World Health Organization. 1 February 2023. Retrieved 2023-06-16.
  44. ^ Siddiqui, A. A.; Siddiqui, B. A.; Ganley-Leal, L. (2011). "Schistosomiasis vaccines". Human Vaccines. 7 (11): 1192–1197. doi:10.4161/hv.7.11.17017. PMC 3323497. PMID 22048120.
  45. ^ Public Domain This article incorporates text from this source, which is in the public domain: Lopez A, Harrington T, Marin M (2015). "Chapter 22: Varicella". In Hamborsky J, Kroger A, Wolfe S (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
  46. ^ "Yaws". World Health Organization. 12 January 2023. Retrieved 2023-06-16.
  47. ^ Cullen, P. A.; Cameron, C. E. (2006). "Progress towards an effective syphilis vaccine: The past, present and future". Expert Review of Vaccines. 5 (1): 67–80. doi:10.1586/14760584.5.1.67. PMID 16451109. S2CID 31534855.
  48. ^ Guilherme, L.; Ferreira, F. M.; Köhler, K. F.; Postol, E.; Kalil, J. (2013). "A Vaccine against Streptococcus pyogenes". American Journal of Cardiovascular Drugs. 13 (1): 1–4. doi:10.1007/s40256-013-0005-8. PMID 23355360. S2CID 13071864.
  49. ^ Bagnoli, F.; Bertholet, S.; Grandi, G. (2012). "Inferring Reasons for the Failure of Staphylococcus aureus Vaccines in Clinical Trials". Frontiers in Cellular and Infection Microbiology. 2: 16. doi:10.3389/fcimb.2012.00016. PMC 3417391. PMID 22919608.
  50. ^ "Trachoma".
  51. ^ Conlan, J. W. (2011). "Tularemia vaccines: Recent developments and remaining hurdles". Future Microbiology. 6 (4): 391–405. doi:10.2217/fmb.11.22. PMID 21526941.
  52. ^ Walsh TJ, Dixon DM (1996). Baron S, et al. (eds.). Spectrum of Mycoses. In: Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1. (via NCBI Bookshelf).
  53. ^ Hall, R. A.; Khromykh, A. A. (2004). "West Nile virus vaccines". Expert Opinion on Biological Therapy. 4 (8): 1295–1305. doi:10.1517/14712598.4.8.1295. PMID 15268663. S2CID 34176756.
  54. ^ Sifferlin, Alexandra (21 January 2016). "U.S. Launches 'Full-court Press' for a Zika Vaccine". Time. Retrieved 23 January 2016.